Home > Insider Trading > Filing (0001181431-12-041391)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1382911	Orexigen Therapeutics Inc.	OREX	Pharmaceutical Preparations (2834)	651178822

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1380022	Michael Narachi	C/O Orexigen Therapeutics, Inc. 3344 N. Torrey Pines Court, Suite 200 La Jolla CA 92037	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-07-17	124,238	$1.66	124,238	No	4	M	Direct
Common Stock	Disposition	2012-07-17	124,238	$7.66	0	No	4	S	Direct
Common Stock	Acquisiton	2012-07-17	25,762	$1.70	25,762	No	4	M	Direct
Common Stock	Disposition	2012-07-17	25,762	$7.66	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2012-07-17	124,238	$0.00	124,238	$1.66
Common Stock	Stock Option (right to buy)	Disposition	2012-07-17	25,762	$0.00	25,762	$1.70

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,761,562		2021-07-24	No	4	M	Direct
1,774,238		2021-06-09	No	4	M	Direct

Footnotes

The exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2012.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2012.
1/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) (which option is referred to in this Form 4 as the "Replacement Grant") shall vest on the same day of each one-month period of the reporting person's service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
Not applicable.
1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest and become exercisable on the same day of each month after June 10, 2011, so that all of the shares of the stock subject to the option shall be vested in full on June 10, 2015, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.